Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

56.33USD
18 Dec 2017
Change (% chg)

$0.09 (+0.16%)
Prev Close
$56.24
Open
$56.38
Day's High
$56.69
Day's Low
$56.22
Volume
2,861,070
Avg. Vol
10,352,304
52-wk High
$66.80
52-wk Low
$53.63

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.77
Market Cap(Mil.): $153,386.41
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.48
Yield (%): 3.41

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

Merck's Keytruda fails pivotal gastric cancer trial

Merck & Co Inc said on Thursday a key late-stage trial testing its blockbuster drug, Keytruda, failed to meet its main goal of extending lives of patients with a type of gastric cancer.

Dec 14 2017

UPDATE 1-Merck's Keytruda fails pivotal gastric cancer trial

Dec 14 Merck & Co Inc said on Thursday a key late-stage trial testing its blockbuster drug, Keytruda, failed to meet its main goal of extending lives of patients with a type of gastric cancer.

Dec 14 2017

Merck's Keytruda fails pivotal gastric cancer trial

Dec 14 Merck & Co Inc said on Thursday a key late-stage trial testing Keytruda failed to meet its main goal of extending the lives of patients with a type of gastric cancer.

Dec 14 2017

BRIEF-Merck Provides Update On Keynote-061, A Phase 3 Study Of Keytruda (Pembrolizumab)

* MERCK PROVIDES UPDATE ON KEYNOTE-061, A PHASE 3 STUDY OF KEYTRUDA® (PEMBROLIZUMAB) IN PREVIOUSLY TREATED PATIENTS WITH GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Dec 14 2017

BRIEF-Merck Says Prevymis To Be Available In Canada By End Of December

* MERCK & CO SAYS RECENTLY APPROVED PREVYMIS (LETERMOVIR) IS EXPECTED TO BE AVAILABLE IN CANADA BY END OF DECEMBER 2017 Source text for Eikon: Further company coverage:

Dec 14 2017

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014

Dec 11 2017

Merck raises stakes in lung cancer as rivals close in

LOS ANGELES Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer.

Dec 11 2017

BRIEF-Neon Therapeutics To Collaborate with Merk on Clinical Trial

* NEON THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION WITH MERCK

Dec 07 2017

BRIEF-Merck's Mavenclad (Cladribine Tablets) Approved For Relapsing-Remitting Multiple Sclerosis In Canada

* MERCK'S MAVENCLAD (CLADRIBINE TABLETS) APPROVED FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA Source text for Eikon: Further company coverage:

Dec 04 2017

UPDATE 2-Health secretary nominee Azar says lowering drug prices a top priority

WASHINGTON, Nov 29 Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, promised on Wednesday to lower drug prices and said he was unaware of any efforts to sabotage the healthcare law passed under former President Barack Obama.

Nov 29 2017

Competitors

Earnings vs. Estimates